Welcome to our dedicated page for Vivopower International Plc SEC filings (Ticker: VIVO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Meridian Bioscience Inc. is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products.The company is dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, Meridian provides critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, Meridian provides diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. The company builds relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.VivoPower PLC director Hui Michael Singee reported his ownership on a Form 3. He holds 33,617 Ordinary Shares directly following the reported position. This filing records his equity stake as an insider but does not show any recent share purchases or sales.
VivoPower PLC chairman and CEO Kevin Chin has filed an initial insider ownership report showing his indirect stakes in the company. The filing lists 4,331,488 Ordinary Shares held through various entities he controls, as well as warrants over 1,200,000 Ordinary Shares held through Awn Holdings, which he also controls. These warrants are exercisable at $1.00 per share and expire on December 31, 2030. The entries are presented as existing holdings rather than new purchases or sales.
VivoPower PLC director Langdon William Hayward filed a Form 3 reporting beneficial ownership of 46,567 Ordinary Shares. The filing classifies this as a holding entry, with shares owned directly and no specific buy or sell transaction reported in the data.
VivoPower PLC is converting 2,961,000 Nasdaq‑listed Class A ordinary shares held by Executive Chairman and CEO Kevin Chin and affiliated entities into the same number of unlisted Class B ordinary shares with enhanced voting rights. These Class B shares are not listed on Nasdaq and are not freely tradable, so the move reduces the publicly tradable float while concentrating voting power with insiders. The conversion follows board and management purchases of 2,650,000 shares on February 18, 2026 and is authorized under a dual‑class structure approved by shareholders on January 30, 2026. VivoPower frames the step as part of a broader, non‑dilutive capital strategy that includes terminating its at‑the‑market equity offering agreement with Chardan and withdrawing a $180M Form F‑3 shelf registration, emphasizing project‑level financing for its AI data center and powered land business rather than new equity issuance at the parent level.